{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:29:28Z","timestamp":1794022168380,"version":"4.8.0"},"reference-count":271,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), is a growing but often unrecognized medical problem for people with diabetes (particularly type 2 diabetes, especially when associated with obesity). Liver health has not been at the forefront of complications tracked for disease prevention, as traditionally done for diabetic retinopathy, nephropathy, or neuropathy. However, liver steatosis affects approximately two out of three people with type 2 diabetes and places them at an increased risk for metabolic dysfunction\u2013associated steatohepatitis (MASH), cirrhosis, hepatocellular carcinoma (HCC), and overall liver-related mortality. MASLD is also associated with extrahepatic cancers, atherosclerotic cardiovascular disease, and progression from prediabetes to type 2 diabetes and negatively impacts health-related quality of life. However, most individuals and their health care professionals remain unaware of the severe hepatic or extrahepatic health risks associated with MASLD and the need for early identification. In recognition of this knowledge gap and the rising prevalence of MASLD, this consensus report is a call to action to screen for liver fibrosis and risk stratify people with prediabetes or type 2 diabetes, in particular if obesity is also present. This consensus report explains the rationale for the recent MASLD nomenclature change, how to best risk stratify, current treatment and long-term monitoring options, the value of an interprofessional approach to disease management, and the impact of alcohol intake on liver health. More awareness about the health risks associated with MASLD and broad adoption of screening for liver fibrosis as a new standard of care hold promise for a future without cirrhosis for people with prediabetes and type 2 diabetes.<\/jats:p>","DOI":"10.2337\/dci24-0094","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:01:43Z","timestamp":1748422903000},"page":"1057-1082","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":397,"title":["Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association"],"prefix":"10.2337","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-418X","authenticated-orcid":false,"given":"Kenneth","family":"Cusi","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida 1 , Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal F.","family":"Abdelmalek","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic 2 , Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Apovian","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Hypertension, Brigham and Women\u2019s Hospital 3 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirthikaa","family":"Balapattabi","sequence":"additional","affiliation":[{"name":"American Diabetes Association 4 , Arlington, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-5783","authenticated-orcid":false,"given":"Raveendhara R.","family":"Bannuru","sequence":"additional","affiliation":[{"name":"American Diabetes Association 4 , Arlington, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Barb","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University of Florida 1 , Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan K.","family":"Bardsley","sequence":"additional","affiliation":[{"name":"MedStar Diabetes Institute 5 , Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Beverly","sequence":"additional","affiliation":[{"name":"Heritage College of Osteopathic Medicine, Ohio University 6 , Athens, OH"},{"name":"Diabetes Institute, Ohio University 7 , Athens, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen D.","family":"Corbin","sequence":"additional","affiliation":[{"name":"AdventHealth Translational Research Institute 8 , Orlando, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuha A.","family":"ElSayed","sequence":"additional","affiliation":[{"name":"American Diabetes Association 4 , Arlington, VA"},{"name":"Harvard Medical School 9 , Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Isaacs","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Lipids, Emory School of Medicine, Emory University 10 , Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fasiha","family":"Kanwal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine 11 , Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Pekas","sequence":"additional","affiliation":[{"name":"American Diabetes Association 4 , Arlington, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Richardson","sequence":"additional","affiliation":[{"name":"The Warren Alpert Medical School of Brown University 12 , Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetology, Medical Faculty, and University Hospital D\u00fcsseldorf, Heinrich-Heine-University D\u00fcsseldorf, D\u00fcsseldorf 13 , Germany"},{"name":"Institute for Clinical Diabetology, German Diabetes Center - Leibniz Center for Diabetes Research at Heinrich-Heine-University D\u00fcsseldorf, D\u00fcsseldorf 14 , Germany"},{"name":"German Center for Diabetes Research, Partner D\u00fcsseldorf, M\u00fcnchen-Neuherberg, D\u00fcsseldorf 15 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Medicine 16 , Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay H.","family":"Shubrook","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences and Community Health, College of Osteopathic Medicine, Touro University California 17 , Vallejo, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zobair M.","family":"Younossi","sequence":"additional","affiliation":[{"name":"The Global NASH Council 18 , Washington, DC"},{"name":"Beatty Liver and Obesity Research Program, Inova Health System 19 , Falls Church, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep","family":"Bajaj","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine 11 , Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"2026061713134417600_B1","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol"},{"key":"2026061713134417600_B3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B4","doi-asserted-by":"crossref","first-page":"109981","DOI":"10.1016\/j.diabres.2022.109981","article-title":"Prevalence of elevated liver stiffness in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"190","author":"Ciardullo","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061713134417600_B5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061713134417600_B6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"2026061713134417600_B7","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013\u20132022: the dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease","volume":"8","author":"Younossi","year":"2024","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B8","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dc23-1085","article-title":"Impact of type 2 diabetes on the outcomes of solid organ transplantations in the U.S.: data from a national registry","volume":"46","author":"Stepanova","year":"2023","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dsi23-0010","article-title":"Understanding the burden of nonalcoholic fatty liver disease: time for action","volume":"37","author":"Younossi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"2026061713134417600_B10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B11","article-title":"ESSENCE Study Group. Phase 3 trial: semaglutide in metabolic dysfunction-associated steatohepatitis","author":"Sanyal"},{"key":"2026061713134417600_B12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2337\/dsi23-0014","article-title":"Making sense of the nonalcoholic fatty liver disease clinical practice guidelines: what clinicians need to know","volume":"37","author":"Cusi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"2026061713134417600_B13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026061713134417600_B14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026061713134417600_B15","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2026061713134417600_B16","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J Hepatol"},{"key":"2026061713134417600_B17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"key":"2026061713134417600_B18","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"Ciardullo","year":"2023","journal-title":"Liver Int"},{"key":"2026061713134417600_B19","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/HEP.0000000000000263","article-title":"Diabetes and cirrhosis: current concepts on diagnosis and management","volume":"77","author":"Castera","year":"2023","journal-title":"Hepatology"},{"key":"2026061713134417600_B20","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/hep.31806","article-title":"Glycemic control predicts severity of hepatocyte ballooning and hepatic fibrosis in nonalcoholic fatty liver disease","volume":"74","author":"Alexopoulos","year":"2021","journal-title":"Hepatology"},{"key":"2026061713134417600_B21","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"2026061713134417600_B22","doi-asserted-by":"crossref","first-page":"e0219855","DOI":"10.1371\/journal.pone.0219855","article-title":"Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis","volume":"14","author":"Colomba","year":"2019","journal-title":"PLoS One"},{"key":"2026061713134417600_B23","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061713134417600_B24","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1097\/HEP.0000000000000706","article-title":"From NAFLD to MASLD: promise and pitfalls of a new definition \u2020","volume":"79","author":"Cusi","year":"2024","journal-title":"Hepatology"},{"key":"2026061713134417600_B25","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00125-009-1620-4","article-title":"The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation","volume":"53","author":"Simmons","year":"2010","journal-title":"Diabetologia"},{"key":"2026061713134417600_B26","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/oby.24130","article-title":"Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen","volume":"32","author":"Sharma","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"2026061713134417600_B27","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1210\/clinem\/dgab645","article-title":"Insulin resistance and cardiometabolic risk profile among nondiabetic American young adults: insights from NHANES","volume":"107","author":"Parcha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061713134417600_B28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jhep.2023.11.004","article-title":"Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"key":"2026061713134417600_B29","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/hep.32228","article-title":"Global burden of NAFLD and chronic liver disease among adolescents and young adults","volume":"75","author":"Paik","year":"2022","journal-title":"Hepatology"},{"key":"2026061713134417600_B30","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B31","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"2026061713134417600_B32","doi-asserted-by":"crossref","first-page":"155642","DOI":"10.1016\/j.metabol.2023.155642","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","volume":"146","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"2026061713134417600_B33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/obr.12157","article-title":"Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies","volume":"15","author":"Bell","year":"2014","journal-title":"Obes Rev"},{"key":"2026061713134417600_B34","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1080\/07853890.2021.1956685","article-title":"Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)","volume":"53","author":"Cuthbertson","year":"2021","journal-title":"Ann Med"},{"key":"2026061713134417600_B35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J Hepatol"},{"key":"2026061713134417600_B36","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol"},{"key":"2026061713134417600_B37","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B38","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2337\/dc22-2048","article-title":"High prevalence of NASH and advanced fibrosis in type 2 diabetes: a prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold","volume":"46","author":"Castera","year":"2023","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3350\/cmh.2023.0485","article-title":"Global incidence of adverse clinical events in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Le","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"2026061713134417600_B40","doi-asserted-by":"crossref","first-page":"e0251","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B41","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2468-1253(21)00100-X","article-title":"Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA","volume":"6","author":"Rich","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061713134417600_B42","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/apt.17158","article-title":"Review article: the epidemiologic burden of non-alcoholic fatty liver disease across the world","volume":"56","author":"Henry","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061713134417600_B43","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026061713134417600_B44","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.cgh.2021.11.029","article-title":"Food insecurity is associated with mortality among U.S. adults with nonalcoholic fatty liver disease and advanced fibrosis","volume":"20","author":"Kardashian","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B45","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.14309\/ajg.0000000000002749","article-title":"Food insecurity, low household income, and low education level increase the risk of having metabolic dysfunction-associated fatty liver disease among adolescents in the United States","volume":"119","author":"Paik","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026061713134417600_B46","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","article-title":"Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"20","author":"Orci","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B47","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B48","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/apt.12881","article-title":"The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US","volume":"40","author":"Younossi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061713134417600_B49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cld.2023.01.007","article-title":"Economic burden and patient-reported outcomes of nonalcoholic fatty liver disease","volume":"27","author":"Stepanova","year":"2023","journal-title":"Clin Liver Dis"},{"key":"2026061713134417600_B50","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"2026061713134417600_B51","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B52","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"2026061713134417600_B53","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.aohep.2020.09.006","article-title":"Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease","volume":"19","author":"Arab","year":"2020","journal-title":"Ann Hepatol"},{"key":"2026061713134417600_B54","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol Int"},{"key":"2026061713134417600_B55","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B56","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"2026061713134417600_B57","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2026061713134417600_B58","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","journal-title":"J Hepatol"},{"key":"2026061713134417600_B59","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B60","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1053\/j.gastro.2020.07.050","article-title":"Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis","volume":"159","author":"Noureddin","year":"2020","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B61","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int"},{"key":"2026061713134417600_B62","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jmri.25006","article-title":"Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference","volume":"43","author":"Heba","year":"2016","journal-title":"J Magn Reson Imaging"},{"key":"2026061713134417600_B63","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1210\/er.2017-00025","article-title":"A reappraisal of testosterone's binding in circulation: physiological and clinical implications","volume":"38","author":"Goldman","year":"2017","journal-title":"Endocr Rev"},{"key":"2026061713134417600_B64","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1053\/jhep.2003.50229","article-title":"Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values","volume":"37","author":"Mofrad","year":"2003","journal-title":"Hepatology"},{"key":"2026061713134417600_B65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hep.27395","article-title":"The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease","volume":"61","author":"Maximos","year":"2015","journal-title":"Hepatology"},{"key":"2026061713134417600_B66","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/liv.12226","article-title":"Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)","volume":"33","author":"Verma","year":"2013","journal-title":"Liver Int"},{"key":"2026061713134417600_B67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7201a1","article-title":"Screening and testing for hepatitis B virus infection: CDC recommendations - United States, 2023","volume":"72","author":"Conners","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"2026061713134417600_B68","doi-asserted-by":"crossref","first-page":"766","DOI":"10.15585\/mmwr.mm7228a2","article-title":"Updated operational guidance for implementing CDC's recommendations on testing for hepatitis C virus infection","volume":"72","author":"Cartwright","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026061713134417600_B69","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/j.cgh.2018.12.031","article-title":"Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage","volume":"17","author":"Siddiqui","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B70","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1136\/gut.2010.216077","article-title":"Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease","volume":"59","author":"McPherson","year":"2010","journal-title":"Gut"},{"key":"2026061713134417600_B71","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hep.29113","article-title":"Liver fibrosis scores predict liver disease mortality in the United States population","volume":"66","author":"Unalp-Arida","year":"2017","journal-title":"Hepatology"},{"key":"2026061713134417600_B72","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","article-title":"Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease","volume":"73","author":"Hagstr\u00f6m","year":"2020","journal-title":"J Hepatol"},{"key":"2026061713134417600_B73","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jhep.2022.10.035","article-title":"Longitudinal changes in fibrosis markers are associated with risk of cirrhosis and hepatocellular carcinoma in non-alcoholic fatty liver disease","volume":"78","author":"Cholankeril","year":"2023","journal-title":"J Hepatol"},{"key":"2026061713134417600_B74","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/liv.14669","article-title":"Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: a systematic review","volume":"41","author":"Lee","year":"2021","journal-title":"Liver Int"},{"key":"2026061713134417600_B75","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/nu15010066","article-title":"The FIB-4 index predicts the development of liver-related events, extrahepatic cancers, and coronary vascular disease in patients with NAFLD","volume":"15","author":"Kamada","year":"2022","journal-title":"Nutrients"},{"key":"2026061713134417600_B76","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.cgh.2023.02.024","article-title":"Validation of a clinical risk-based classification system in a large nonalcoholic fatty liver disease real-world cohort","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B77","doi-asserted-by":"crossref","first-page":"100780","DOI":"10.1016\/j.lanepe.2023.100780","article-title":"Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study","volume":"36","author":"Anstee","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2026061713134417600_B78","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061713134417600_B79","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.32739","article-title":"Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population","volume":"77","author":"Udompap","year":"2023","journal-title":"Hepatology"},{"key":"2026061713134417600_B80","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jhep.2021.12.031","article-title":"Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events","volume":"76","author":"Boursier","year":"2022","journal-title":"J Hepatol"},{"key":"2026061713134417600_B81","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"key":"2026061713134417600_B82","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive assessment of liver fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B83","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"2026061713134417600_B84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hep.21984","article-title":"Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers","volume":"47","author":"Guha","year":"2008","journal-title":"Hepatology"},{"key":"2026061713134417600_B85","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jhep.2013.03.016","article-title":"The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values","volume":"59","author":"Lichtinghagen","year":"2013","journal-title":"J Hepatol"},{"key":"2026061713134417600_B86","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"key":"2026061713134417600_B87","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1038\/s41591-023-02539-6","article-title":"Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"2026061713134417600_B88","doi-asserted-by":"crossref","first-page":"101062","DOI":"10.1016\/j.jhepr.2024.101062","article-title":"Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality","volume":"6","author":"Pearson","year":"2024","journal-title":"JHEP Rep"},{"key":"2026061713134417600_B89","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B90","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"key":"2026061713134417600_B91","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/hep4.1208","article-title":"A pragmatic approach identifies a high rate of nonalcoholic fatty liver disease with advanced fibrosis in diabetes clinics and at-risk populations in primary care","volume":"2","author":"Patel","year":"2018","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B92","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.cgh.2023.11.022","article-title":"Accuracy of the enhanced liver fibrosis test in patients with type 2 diabetes mellitus and its clinical implications","volume":"22","author":"Arai","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B93","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2016.06.005","article-title":"MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice","volume":"65","author":"Dulai","year":"2016","journal-title":"J Hepatol"},{"key":"2026061713134417600_B94","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cgh.2021.09.041","article-title":"Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis","volume":"20","author":"Andersson","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B95","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B96","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cgh.2018.05.059","article-title":"Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants","volume":"17","author":"Hsu","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B97","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1007\/s00330-023-10441-5","article-title":"A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone","volume":"34","author":"Duman","year":"2024","journal-title":"Eur Radiol"},{"key":"2026061713134417600_B98","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography","volume":"79","author":"Liang","year":"2023","journal-title":"J Hepatol"},{"key":"2026061713134417600_B99","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"2026061713134417600_B100","doi-asserted-by":"crossref","first-page":"723","DOI":"10.14309\/ajg.0000000000000994","article-title":"Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease","volume":"116","author":"Pons","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"2026061713134417600_B101","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","article-title":"Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores","volume":"78","author":"Sanyal","year":"2023","journal-title":"J Hepatol"},{"key":"2026061713134417600_B102","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2023.04.031","article-title":"NIS2+, an optimisation of the blood-based biomarker NIS4 technology for the detection of at-risk NASH: a prospective derivation and validation study","volume":"79","author":"Harrison","year":"2023","journal-title":"J Hepatol"},{"key":"2026061713134417600_B103","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000223","article-title":"NIS2+, an effective blood-based test for the diagnosis of at-risk nonalcoholic steatohepatitis in adults 65 years and older","volume":"7","author":"Sanyal","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B104","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.jhep.2021.11.012","article-title":"MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis","volume":"76","author":"Noureddin","year":"2022","journal-title":"J Hepatol"},{"key":"2026061713134417600_B105","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/apt.17707","article-title":"MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-individual participant data meta-analyses","volume":"58","author":"Noureddin","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061713134417600_B106","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/HEP.0000000000000542","article-title":"Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF)","volume":"79","author":"Noureddin","year":"2024","journal-title":"Hepatology"},{"key":"2026061713134417600_B107","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hep4.1841","article-title":"Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD","volume":"6","author":"Vieira Barbosa","year":"2022","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B108","doi-asserted-by":"crossref","first-page":"1172178","DOI":"10.3389\/fcvm.2023.1172178","article-title":"Association between FIB-4, all-cause mortality, cardiovascular mortality, and cardiovascular disease risk among diabetic individuals: NHANES 1999-2008","volume":"10","author":"Guan","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"2026061713134417600_B109","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/hep.31142","article-title":"Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study","volume":"72","author":"Lee","year":"2020","journal-title":"Hepatology"},{"key":"2026061713134417600_B110","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026061713134417600_B111","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","article-title":"Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study","volume":"37","author":"Yuan","year":"2022","journal-title":"Eur J Epidemiol"},{"key":"2026061713134417600_B112","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2337\/dc23-1937","article-title":"Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes","volume":"47","author":"Shang","year":"2024","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B113","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2337\/dc11-1849","article-title":"Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD)","volume":"35","author":"Ortiz-Lopez","year":"2012","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B114","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc15-1876","article-title":"Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes","volume":"39","author":"Lomonaco","year":"2016","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B115","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B116","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","article-title":"Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Shah","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B117","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","article-title":"Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","volume":"81","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"2026061713134417600_B118","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HEP.0000000000000351","article-title":"Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes","volume":"78","author":"Pennisi","year":"2023","journal-title":"Hepatology"},{"key":"2026061713134417600_B119","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061713134417600_B120","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","article-title":"Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study","volume":"76","author":"Rinella","year":"2022","journal-title":"J Hepatol"},{"key":"2026061713134417600_B121","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1136\/gutjnl-2023-330269","article-title":"Clinical care pathway to detect advanced liver disease in patients with type 2 diabetes through automated fibrosis score calculation and electronic reminder messages: a randomised controlled trial","volume":"72","author":"Zhang","year":"2023","journal-title":"Gut"},{"key":"2026061713134417600_B122","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B123","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/dsi23-0009","article-title":"Practical lifestyle management of nonalcoholic fatty liver disease for busy clinicians","volume":"37","author":"Zelber-Sagi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"2026061713134417600_B124","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"2026061713134417600_B126","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc25-S005","article-title":"5. Facilitating positive health behaviors and well-being to improve health outcomes: Standards of Care in Diabetes\u20142025","volume":"48","author":"Amercian Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B127","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2337\/dci19-0014","article-title":"Nutrition therapy for adults with diabetes or prediabetes: a consensus report","volume":"42","author":"Evert","year":"2019","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B128","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2018.01.019","article-title":"Fructose and sugar: a major mediator of non-alcoholic fatty liver disease","volume":"68","author":"Jensen","year":"2018","journal-title":"J Hepatol"},{"key":"2026061713134417600_B129","doi-asserted-by":"crossref","first-page":"e13659","DOI":"10.1111\/eci.13659","article-title":"Is there an 'ideal' diet for patients with NAFLD?","volume":"52","author":"Pugliese","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"2026061713134417600_B130","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.30076","article-title":"Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: a randomized controlled trial","volume":"68","author":"Properzi","year":"2018","journal-title":"Hepatology"},{"key":"2026061713134417600_B131","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","article-title":"The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"41","author":"Haigh","year":"2022","journal-title":"Clin Nutr"},{"key":"2026061713134417600_B132","doi-asserted-by":"crossref","first-page":"154439","DOI":"10.1016\/j.metabol.2020.154439","article-title":"Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus","volume":"115","author":"Blomdahl","year":"2021","journal-title":"Metabolism"},{"key":"2026061713134417600_B133","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/obr.12719","article-title":"The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis","volume":"19","author":"Sargeant","year":"2018","journal-title":"Obes Rev"},{"key":"2026061713134417600_B134","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.dld.2022.12.013","article-title":"Effect of exercise-based interventions in nonalcoholic fatty liver disease: a systematic review with meta-analysis","volume":"55","author":"Nam","year":"2023","journal-title":"Dig Liver Dis"},{"key":"2026061713134417600_B135","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.14309\/ajg.0000000000002098","article-title":"Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"118","author":"Stine","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"2026061713134417600_B136","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cgh.2016.04.036","article-title":"Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression","volume":"14","author":"Orci","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B137","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/ajg.2010.488","article-title":"Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease","volume":"106","author":"Kistler","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"2026061713134417600_B138","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1249\/MSS.0000000000003199","article-title":"Physical activity and nonalcoholic fatty liver disease: a roundtable statement from the American College of Sports Medicine","volume":"55","author":"Stine","year":"2023","journal-title":"Med Sci Sports Exerc"},{"key":"2026061713134417600_B139","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2016.08.023","article-title":"Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review","volume":"66","author":"Hashida","year":"2017","journal-title":"J Hepatol"},{"key":"2026061713134417600_B140","doi-asserted-by":"crossref","first-page":"1357664","DOI":"10.3389\/fendo.2024.1357664","article-title":"Non-alcoholic fatty liver disease and coexisting depression, anxiety and\/or stress in adults: a systematic review and meta-analysis","volume":"15","author":"Shea","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026061713134417600_B141","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2337\/dci20-0023","article-title":"Diabetes self-management education and support in adults with type 2 diabetes: a consensus report of the American Diabetes Association, the Association of Diabetes Care & Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association","volume":"43","author":"Powers","year":"2020","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B142","doi-asserted-by":"crossref","first-page":"e0224","DOI":"10.1097\/HC9.0000000000000224","article-title":"Behavioral weight-loss interventions for patients with NAFLD: a systematic scoping review","volume":"7","author":"Balakrishnan","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B143","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.2337\/dc06-0560","article-title":"Effect of weight loss with lifestyle intervention on risk of diabetes","volume":"29","author":"Hamman","year":"2006","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B144","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2026061713134417600_B145","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/oby.2011.230","article-title":"Four-year weight losses in the Look AHEAD study: factors associated with long-term success","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"2026061713134417600_B146","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B147","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/liv.15209","article-title":"Knowledge of liver fibrosis stage among adults with NAFLD\/NASH improves adherence to lifestyle changes","volume":"42","author":"Carrieri","year":"2022","journal-title":"Liver Int"},{"key":"2026061713134417600_B148","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cgh.2018.10.044","article-title":"Barriers and facilitators to Mediterranean diet adoption by patients with nonalcoholic fatty liver disease in Northern Europe","volume":"17","author":"Haigh","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B149","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.3748\/wjg.v23.i10.1881","article-title":"Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients","volume":"23","author":"Zelber-Sagi","year":"2017","journal-title":"World J Gastroenterol"},{"key":"2026061713134417600_B150","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061713134417600_B151","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B152","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"11. Chronic kidney disease and risk management: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B153","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B154","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B155","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061713134417600_B156","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B157","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"2026061713134417600_B158","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B159","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"2026061713134417600_B160","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B161","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"key":"2026061713134417600_B162","first-page":"90","article-title":"Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2018","journal-title":"Biomed Rep"},{"key":"2026061713134417600_B163","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061713134417600_B164","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2337\/dsi23-0012","article-title":"Pharmacological approaches to nonalcoholic fatty liver disease: current and future therapies","volume":"37","author":"Genua","year":"2024","journal-title":"Diabetes Spectr"},{"key":"2026061713134417600_B165","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1001\/jama.2024.0318","article-title":"Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes","volume":"331","author":"Courcoulas","year":"2024","journal-title":"JAMA"},{"key":"2026061713134417600_B166","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1007\/s11695-017-2866-4","article-title":"The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis","volume":"27","author":"Sheng","year":"2017","journal-title":"Obes Surg"},{"key":"2026061713134417600_B167","doi-asserted-by":"crossref","first-page":"101495","DOI":"10.1016\/j.diabet.2023.101495","article-title":"French National Authority for Health assessment of metabolic surgery for type 2 diabetes remission-a meta-analysis in patients with class I to III obesity","volume":"50","author":"Lafarge","year":"2024","journal-title":"Diabetes Metab"},{"key":"2026061713134417600_B168","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.soard.2023.08.016","article-title":"Benefits of metabolic surgery on macrovascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis","volume":"20","author":"Obeso-Fern\u00e1ndez","year":"2024","journal-title":"Surg Obes Relat Dis"},{"key":"2026061713134417600_B169","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.soard.2018.12.002","article-title":"Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis","volume":"15","author":"Fakhry","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"2026061713134417600_B170","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/apt.16335","article-title":"Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma","volume":"53","author":"Ramai","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026061713134417600_B171","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.3390\/ijms24076192","article-title":"Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk","volume":"24","author":"Wilson","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026061713134417600_B172","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"326","author":"Aminian","year":"2021","journal-title":"JAMA"},{"key":"2026061713134417600_B173","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.soard.2020.11.004","article-title":"Safety of metabolic and bariatric surgery in obese patients with liver cirrhosis: a systematic review and meta-analysis","volume":"17","author":"Agarwal","year":"2021","journal-title":"Surg Obes Relat Dis"},{"key":"2026061713134417600_B174","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tem.2024.05.009","article-title":"Recompensation in MASLD-related cirrhosis via metabolic bariatric surgery","volume":"36","author":"Feng","year":"2025","journal-title":"Trends Endocrinol Metab"},{"key":"2026061713134417600_B175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"key":"2026061713134417600_B176","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B177","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"2026061713134417600_B178","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2026061713134417600_B179","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-0041-1732354","article-title":"Novel antidiabetic strategies and diabetologists' views in nonalcoholic steatohepatitis","volume":"42","author":"Kahl","year":"2022","journal-title":"Semin Liver Dis"},{"key":"2026061713134417600_B180","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.2147\/PPA.S277676","article-title":"Real-world adherence and discontinuation of glucagon-like peptide-1 receptor agonists therapy in type 2 diabetes mellitus patients in the United States","volume":"14","author":"Weiss","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2026061713134417600_B181","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002517","article-title":"Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK","volume":"10","author":"Weiss","year":"2022","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026061713134417600_B182","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B183","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"2026061713134417600_B184","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","article-title":"First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"key":"2026061713134417600_B185","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B186","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B187","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"2026061713134417600_B188","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B189","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diacare.25.3.517","article-title":"Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes","volume":"25","author":"Miyazaki","year":"2002","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B190","doi-asserted-by":"crossref","first-page":"108984","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","volume":"178","author":"Della Pepa","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061713134417600_B191","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.clinthera.2012.09.007","article-title":"Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years","volume":"34","author":"Norwood","year":"2012","journal-title":"Clin Ther"},{"key":"2026061713134417600_B192","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B193","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1111\/dom.14153","article-title":"Combination therapy with pioglitazone\/exenatide improves beta-cell function and produces superior glycaemic control compared with basal\/bolus insulin in poorly controlled type 2 diabetes: a 3-year follow-up of the Qatar study","volume":"22","author":"Abdul-Ghani","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"2026061713134417600_B194","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1111\/dom.15576","article-title":"Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: a systematic review, meta-analysis, and real-world study from an international federated database","volume":"26","author":"Anson","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026061713134417600_B195","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026061713134417600_B196","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/dom.14650","article-title":"Combination therapy with pioglitazone\/exenatide\/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)","volume":"24","author":"Lavynenko","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2026061713134417600_B197","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/dom.12188","article-title":"Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial","volume":"16","author":"Kovacs","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"2026061713134417600_B198","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.clinthera.2015.05.511","article-title":"Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus","volume":"37","author":"Kovacs","year":"2015","journal-title":"Clin Ther"},{"key":"2026061713134417600_B199","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.12652","article-title":"Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor","volume":"18","author":"DeFronzo","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2026061713134417600_B200","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/hep4.1993","article-title":"Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial","volume":"6","author":"Yoneda","year":"2022","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B201","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/oby.2011.152","article-title":"Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes","volume":"19","author":"Sathyanarayana","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"2026061713134417600_B202","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12876-023-02948-4","article-title":"Effect of empagliflozin and pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial","volume":"23","author":"Attaran","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"2026061713134417600_B203","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"2026061713134417600_B204","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/MCG.0000000000001142","article-title":"Haptoglobin 2 allele is associated with histologic response to vitamin E in subjects with nonalcoholic steatohepatitis","volume":"53","author":"Banini","year":"2019","journal-title":"J Clin Gastroenterol"},{"key":"2026061713134417600_B205","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B206","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"key":"2026061713134417600_B207","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1158\/1055-9965.EPI-09-0013","article-title":"Dietary supplement use and prostate cancer risk in the Carotene and Retinol Efficacy Trial","volume":"18","author":"Neuhouser","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026061713134417600_B208","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B209","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B210","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.dld.2023.09.023","article-title":"Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors","volume":"56","author":"Lombardi","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026061713134417600_B211","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr Rev"},{"key":"2026061713134417600_B212","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1089\/dia.2023.0389","article-title":"Weight gain and glycemic control in adults with type 1 diabetes in the T1D Exchange Registry","volume":"26","author":"Bailey","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"2026061713134417600_B213","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/dom.12973","article-title":"Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes","volume":"19","author":"Cusi","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2026061713134417600_B214","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.12751","article-title":"Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes","volume":"18","author":"Cusi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"2026061713134417600_B215","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tem.2022.08.001","article-title":"NAFLD and thyroid function: pathophysiological and therapeutic considerations","volume":"33","author":"Hatziagelaki","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"2026061713134417600_B216","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/HEP.0000000000001112","article-title":"Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance","volume":"81","author":"Chen","year":"2025","journal-title":"Hepatology"},{"key":"2026061713134417600_B217","doi-asserted-by":"crossref","first-page":"101683","DOI":"10.1016\/j.beem.2022.101683","article-title":"Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders","volume":"36","author":"Guzelce","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026061713134417600_B218","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMe2314365","article-title":"Selective agonists of thyroid hormone receptor beta for the treatment of NASH","volume":"390","author":"Cusi","year":"2024","journal-title":"N Engl J Med"},{"key":"2026061713134417600_B219","unstructured":"Center for Drug Evaluation and Research. Application Number: 217785Orig1s000. NDA 217785: REZDIFFRA (Resmetirom): Integrated Review. U.S. Food & Drug Administration. Accessed 16 August 2024. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217785Orig1s000IntegratedR.pdf"},{"key":"2026061713134417600_B220","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2026061713134417600_B221","doi-asserted-by":"crossref","first-page":"154822","DOI":"10.1016\/j.metabol.2021.154822","article-title":"Preparing for the NASH epidemic: a call to action","volume":"122","author":"Kanwal","year":"2021","journal-title":"Metabolism"},{"key":"2026061713134417600_B222","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors","volume":"79","author":"Muzurovi\u0107","year":"2022","journal-title":"Hypertension"},{"key":"2026061713134417600_B223","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.31608","article-title":"Hepatic fibrosis associates with multiple cardiometabolic disease risk factors: the Framingham Heart Study","volume":"73","author":"Long","year":"2021","journal-title":"Hepatology"},{"key":"2026061713134417600_B224","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/dsi23-0015","article-title":"Nonalcoholic fatty liver disease in diabetes: a call to action","volume":"37","author":"Cusi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"2026061713134417600_B225","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eprac.2023.06.012","article-title":"Identification of high-risk patients with nonalcoholic fatty liver disease in endocrinology clinics","volume":"29","author":"Younossi","year":"2023","journal-title":"Endocr Pract"},{"key":"2026061713134417600_B226","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jand.2017.10.002","article-title":"Academy of Nutrition and Dietetics: revised 2017 scope of practice for the registered dietitian nutritionist","volume":"118","author":"Academy Quality Management Committee","year":"2018","journal-title":"J Acad Nutr Diet"},{"key":"2026061713134417600_B227","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1464-5491.2010.03093.x","article-title":"High prevalence of diabetes mellitus in patients with liver cirrhosis","volume":"27","author":"Wlazlo","year":"2010","journal-title":"Diabet Med"},{"key":"2026061713134417600_B228","doi-asserted-by":"crossref","first-page":"e3157","DOI":"10.1002\/dmrr.3157","article-title":"Prevalence of diabetes in liver cirrhosis: a systematic review and meta-analysis","volume":"35","author":"Lee","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"2026061713134417600_B229","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1535370217744511","article-title":"Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma","volume":"243","author":"Makol","year":"2018","journal-title":"Exp Biol Med (Maywood)"},{"key":"2026061713134417600_B230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jceh.2021.07.001","article-title":"Diabetes mellitus increases the risk of significant hepatic fibrosis in patients with non-alcoholic fatty liver disease","volume":"12","author":"Chhabra","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"2026061713134417600_B231","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.metabol.2016.02.014","article-title":"Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease","volume":"65","author":"Mota","year":"2016","journal-title":"Metabolism"},{"key":"2026061713134417600_B232","doi-asserted-by":"crossref","first-page":"8731","DOI":"10.3390\/ijms25168731","article-title":"Pathophysiological relationship between type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: novel therapeutic approaches","volume":"25","author":"Ferdous","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026061713134417600_B233","doi-asserted-by":"crossref","first-page":"111846","DOI":"10.1016\/j.diabres.2024.111846","article-title":"Diabetes as a risk factor for MASH progression","volume":"217","author":"Gancheva","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061713134417600_B234","doi-asserted-by":"crossref","first-page":"e15437","DOI":"10.1111\/dme.15437","article-title":"Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: a systematic review of longitudinal population-based studies","volume":"41","author":"Khanmohammadi","year":"2024","journal-title":"Diabet Med"},{"key":"2026061713134417600_B235","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B236","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.2337\/dc25-S007","article-title":"7. Diabetes technology: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B237","doi-asserted-by":"crossref","first-page":"e220262","DOI":"10.1001\/jamanetworkopen.2022.0262","article-title":"Analysis of severe hypoglycemia among adults with type 2 diabetes and nonalcoholic fatty liver disease","volume":"5","author":"Lee","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026061713134417600_B238","doi-asserted-by":"crossref","first-page":"962337","DOI":"10.3389\/fmed.2022.962337","article-title":"Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes","volume":"9","author":"Yen","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026061713134417600_B239","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.2337\/dc25-S006","article-title":"6. Glycemic goals and hypoglycemia: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clnu.2023.11.008","article-title":"Prevalence of and associated factors for sarcopenia in patients with liver cirrhosis: a systematic review and meta-analysis","volume":"43","author":"Tuo","year":"2024","journal-title":"Clin Nutr"},{"key":"2026061713134417600_B241","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.1038\/s41598-020-64141-x","article-title":"Clinical performance of flash glucose monitoring system in patients with liver cirrhosis and diabetes mellitus","volume":"10","author":"Costa","year":"2020","journal-title":"Sci Rep"},{"key":"2026061713134417600_B242","doi-asserted-by":"crossref","first-page":"e0195028","DOI":"10.1371\/journal.pone.0195028","article-title":"Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring","volume":"13","author":"Honda","year":"2018","journal-title":"PLoS One"},{"key":"2026061713134417600_B243","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1038\/ctg.2016.38","article-title":"Changes in hepatic venous pressure gradient induced by physical exercise in cirrhosis: results of a pilot randomized open clinical trial","volume":"7","author":"Mac\u00edas-Rodr\u00edguez","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"2026061713134417600_B244","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.28992","article-title":"Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study","volume":"65","author":"Berzigotti","year":"2017","journal-title":"Hepatology"},{"key":"2026061713134417600_B245","doi-asserted-by":"crossref","first-page":"e12774","DOI":"10.1097\/MD.0000000000012774","article-title":"Exercise as an intervention for patients with end-stage liver disease: systematic review","volume":"97","author":"Locklear","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2026061713134417600_B246","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.jhep.2015.01.017","article-title":"Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis","volume":"62","author":"Piguet","year":"2015","journal-title":"J Hepatol"},{"key":"2026061713134417600_B247","first-page":"317","article-title":"Introducing physical exercise as a potential strategy in liver cancer prevention and development","volume":"14","author":"Zamanian-Azodi","year":"2021","journal-title":"Gastroenterol Hepatol Bed Bench"},{"key":"2026061713134417600_B248","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B249","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061713134417600_B250","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"key":"2026061713134417600_B251","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.diabres.2006.08.017","article-title":"Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: postmarketing surveillance study in Japan","volume":"76","author":"Kawamori","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"2026061713134417600_B252","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern Med"},{"key":"2026061713134417600_B253","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence","volume":"4","author":"El-Serag","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061713134417600_B254","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/hep.29660","article-title":"Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies","volume":"67","author":"Simon","year":"2018","journal-title":"Hepatology"},{"key":"2026061713134417600_B255","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/ajg.2014.132","article-title":"Mortality from chronic liver diseases in diabetes","volume":"109","author":"Zoppini","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2026061713134417600_B256","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026061713134417600_B257","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","article-title":"Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis","volume":"8","author":"Huang","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026061713134417600_B258","doi-asserted-by":"crossref","first-page":"e0280","DOI":"10.1097\/HC9.0000000000000280","article-title":"Diabetes and the risk of cirrhosis and HCC: an analysis of the UK Biobank","volume":"7","author":"Ye","year":"2023","journal-title":"Hepatol Commun"},{"key":"2026061713134417600_B259","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.32244","article-title":"Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease","volume":"75","author":"Kramer","year":"2022","journal-title":"Hepatology"},{"key":"2026061713134417600_B260","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ajg.2013.5","article-title":"Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis","volume":"108","author":"Singh","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2026061713134417600_B261","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/gutjnl-2023-330962","article-title":"Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes","volume":"73","author":"Wester","year":"2024","journal-title":"Gut"},{"key":"2026061713134417600_B262","doi-asserted-by":"crossref","first-page":"569","DOI":"10.7326\/M14-1650","article-title":"Effects of initiating moderate alcohol intake on cardiometabolic risk in adults with type 2 diabetes: a 2-year randomized, controlled trial","volume":"163","author":"Gepner","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026061713134417600_B263","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2337\/dc09-0227","article-title":"Alcohol as a risk factor for type 2 diabetes: a systematic review and meta-analysis","volume":"32","author":"Baliunas","year":"2009","journal-title":"Diabetes Care"},{"key":"2026061713134417600_B264","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cncr.20427","article-title":"Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S","volume":"101","author":"Yuan","year":"2004","journal-title":"Cancer"},{"key":"2026061713134417600_B265","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2002.36780","article-title":"Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus","volume":"36","author":"Hassan","year":"2002","journal-title":"Hepatology"},{"key":"2026061713134417600_B266","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/alcalc\/agab042","article-title":"Alcohol consumption is a modifiable risk factor for breast cancer: are women aware of this relationship?","volume":"57","author":"Agabio","year":"2022","journal-title":"Alcohol Alcohol"},{"key":"2026061713134417600_B267","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.alcohol.2006.06.003","article-title":"Alcohol and the risk of colon and rectal cancer with mutations in the K-ras gene","volume":"38","author":"Bongaerts","year":"2006","journal-title":"Alcohol"},{"key":"2026061713134417600_B268","doi-asserted-by":"crossref","first-page":"e2424495","DOI":"10.1001\/jamanetworkopen.2024.24495","article-title":"Alcohol consumption patterns and mortality among older adults with health-related or socioeconomic risk factors","volume":"7","author":"Ortol\u00e1","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026061713134417600_B269","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3945\/ajcn.111.023754","article-title":"Joint association of glycemic load and alcohol intake with type 2 diabetes incidence in women","volume":"94","author":"Mekary","year":"2011","journal-title":"Am J Clin Nutr"},{"key":"2026061713134417600_B270","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1111\/j.1530-0277.2000.tb00003.x","article-title":"Inactive aldehyde dehydrogenase 2 worsens glycemic control in patients with type 2 diabetes mellitus who drink low to moderate amounts of alcohol","volume":"24","author":"Murata","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"key":"2026061713134417600_B271","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/jdi.14108","article-title":"The association between alcohol drinking and glycemic management among people with type 2 diabetes in China","volume":"15","author":"Ye","year":"2024","journal-title":"J Diabetes Investig"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/7\/1057\/811055\/dci240094.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/48\/7\/1057\/811055\/dci240094.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:14:24Z","timestamp":1781716464000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/48\/7\/1057\/160536\/Metabolic-Dysfunction-Associated-Steatotic-Liver"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":271,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,5,28]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dci24-0094","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}